Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/PL-6983> ?p ?o }
Showing triples 1 to 43 of
43
with 100 triples per page.
- PL-6983 abstract "PL-6983 is a selective MC4 receptor agonist which is under development by Palatin Technologies for the treatment of female sexual dysfunction and erectile dysfunction. It was developed as a successor to/replacement of bremelanotide (PT-141) due to concerns of a side effect of increased blood pressure seen with the latter in clinical trials. Relative to bremelanotide, PL-6983 produces significantly lower increases in blood pressure in animal models.".
- PL-6983 wikiPageExternalLink 81244763.
- PL-6983 wikiPageExternalLink pl-6983.pdf.
- PL-6983 wikiPageExternalLink 6983.asp.
- PL-6983 wikiPageID "18239247".
- PL-6983 wikiPageLength "2415".
- PL-6983 wikiPageOutDegree "17".
- PL-6983 wikiPageRevisionID "674580810".
- PL-6983 wikiPageWikiLink Agonist.
- PL-6983 wikiPageWikiLink Animal_model.
- PL-6983 wikiPageWikiLink Blood_pressure.
- PL-6983 wikiPageWikiLink Bremelanotide.
- PL-6983 wikiPageWikiLink Category:Aphrodisiacs.
- PL-6983 wikiPageWikiLink Category:Erectile_dysfunction_drugs.
- PL-6983 wikiPageWikiLink Category:Female_sexual_dysfunction_drugs.
- PL-6983 wikiPageWikiLink Category:Melanocortin_receptor_agonists.
- PL-6983 wikiPageWikiLink Clinical_trial.
- PL-6983 wikiPageWikiLink Erectile_dysfunction.
- PL-6983 wikiPageWikiLink Female_sexual_arousal_disorder.
- PL-6983 wikiPageWikiLink Female_sexual_dysfunction.
- PL-6983 wikiPageWikiLink Melanocortin_4_receptor.
- PL-6983 wikiPageWikiLink Melanotan_II.
- PL-6983 wikiPageWikiLink Model_organism.
- PL-6983 wikiPageWikiLink PF-00446687.
- PL-6983 wikiPageWikiLink Palatin_Technologies.
- PL-6983 wikiPageWikiLink Side_effect.
- PL-6983 wikiPageWikiLink THIQ.
- PL-6983 wikiPageWikiLinkText "PL-6983".
- PL-6983 hasPhotoCollection PL-6983.
- PL-6983 wikiPageUsesTemplate Template:Neuropeptidergics.
- PL-6983 wikiPageUsesTemplate Template:Reflist.
- PL-6983 wikiPageUsesTemplate Template:Sexual_dysfunction_pharmacotherapies.
- PL-6983 subject Category:Aphrodisiacs.
- PL-6983 subject Category:Erectile_dysfunction_drugs.
- PL-6983 subject Category:Female_sexual_dysfunction_drugs.
- PL-6983 subject Category:Melanocortin_receptor_agonists.
- PL-6983 hypernym Agonist.
- PL-6983 type Drug.
- PL-6983 comment "PL-6983 is a selective MC4 receptor agonist which is under development by Palatin Technologies for the treatment of female sexual dysfunction and erectile dysfunction. It was developed as a successor to/replacement of bremelanotide (PT-141) due to concerns of a side effect of increased blood pressure seen with the latter in clinical trials. Relative to bremelanotide, PL-6983 produces significantly lower increases in blood pressure in animal models.".
- PL-6983 label "PL-6983".
- PL-6983 sameAs m.0138ggrr.
- PL-6983 wasDerivedFrom PL-6983?oldid=674580810.
- PL-6983 isPrimaryTopicOf PL-6983.